BioCentury | Dec 16, 2020
Management Tracks

Sage puts pieces in place for growth as Greene, an architect of Alnylam, becomes CEO

...execution, culminating in the launch of Velcade bortezomib...
BioCentury | Aug 7, 2020
Management Tracks

Greene, an architect of Alnylam, looks to the next chapter

...of oncology he led global cancer strategy and execution, culminating in the launch of Velcade bortezomib...
BioCentury | May 30, 2020
Product Development

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

...detailed data from the Phase III BOSTON trial that showed Xpovio selinexor plus once-weekly Velcade bortezomib...
BioCentury | Mar 3, 2020
Product Development

Following Phase III readout, Karyopharm seeks approval of Xpovio for second-line MM

...In about 402 second- to fourth-line MM patients in BOSTON, once-weekly Xpovio plus Velcade bortezomib...
...J.P. Morgan, Morgan Stanley and Jefferies. Targets XPO1 (CRM1) - Exportin 1 Sandi Wong, Assistant Editor Velcade, bortezomib...
BioCentury | Dec 18, 2019

The proteasome-regulating kinase DYRK2 as a target in breast cancer and multiple myeloma

...In both a xenograft mouse model of MM resistant to the marketed MM drug Velcade bortezomib...
BioCentury | Dec 13, 2019
Company News

Novartis gains CHMP support for Eylea competitor in wet AMD

...an anti-CD-38 mAb from the Janssen-Cilag International NV unit of Johnson & Johnson (NYSE:JNJ), with bortezomib...
BioCentury | Aug 16, 2019
Emerging Company Profile

Grace: seeking cures in pathological roots

...Bertozzi’s work suggests NGLY1 inhibitors can boost the antitumor efficacy of proteasome inhibitors carfilzomib and bortezomib...
BioCentury | Jul 10, 2019
Clinical News

July 10 Clinical Quick Takes: Darzalex quad combo raises MM complete response, plus Geneos and ViiV

...Phase II Genmab A/S (CSE:GEN; Pink:GMXAY) said Darzalex daratumumab in combination with Revlimid lenalidomide, Velcade bortezomib...
BioCentury | Jul 3, 2019
Company News

After negative panel vote, FDA approves Karyopharm's multiple myeloma drug

...subgroup data from the Phase IIb STORM study. The event-driven BOSTON is evaluating Xpovio, Velcade bortezomib...
BioCentury | May 31, 2019
Company News

May 31 Company Quick Takes: NMPA accepts two BeiGene applications, approves Hengrui's PD-1 inhibitor; and more

...received Priority Review from FDA for an sBLA for Darzalex daratumumab in combination with Velcade bortezomib...
...ineligible for ASCT. Jonathan Block, Associate Editor Abraxane, nab-paclitaxel (ABI-007) Camrelizumab (INCSHR1210, SHR-1210) Darzalex, daratumumab (JNJ-54767414, humax-cd38) sintilimab (IBI308) tislelizumab (BGB-A317) Velcade, bortezomib...
Items per page:
1 - 10 of 795